RVPH has one compound theyāre actively working on. IBRX has 16 or 17 trials ongoing with several of them at late stage. The FDA didnāt have issues with IBRXās bladder cancer drug or the results. I think IBRXās CEO, Patrick Soon-Shiong, has a meeting w/FDA to find out exactly what needs to happen with the manufacturing facilities. Then, he has to decide how much money and time that will take, so he can reapply for permission to market the drug. Then, heāll decide whether to foot the bill himself or partner w/big pharma before the drug gets approved. Of course, he wants to partner >after< the bladder drug is approved to get full value. My take is heāll foot the bill himself (heās already pumped $700 million into the company), wait for FDA approval, and, then, partner w/big pharma. If something was seriously flawed with IBRXās drug, the stock would be trading under a dollarā¦instead of where it was two weeks ago. Finally, the real losers today are the patients who couldāve benefited from this medication. The FDA should be completely gutted and retooled.